After nearly a decade of work, AstraZeneca axes WEE1 and culls Moderna-partnered drug
Nine years after doling out $50 million upfront to Merck, it appears AstraZeneca’s work in the WEE1 inhibitor space is over.
The UK Big Pharma has ended two studies of adavosertib, a Phase I trial in solid tumors in combo with PD-1 Imfinzi and a Phase II study testing the drug in patients with ovarian cancer, solid tumors and uterine serous cancer.
The company’s top oncology R&D executive, Susan Galbraith, said WEE1 “remains an important target” but the company has gone in a different direction because AstraZeneca wants a pipeline focused on “products that we think have a greater transformative ability for the treatment of patients with cancer.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.